Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors. - EPO and DGF

Central Manchester and Manchester Children's University Hospitals NHS Trust0 个研究点目标入组 40 人开始时间: 2007年5月30日最近更新: 2019年11月25日

试验速览

暂无简介。

•1.Men and women aged = or > 18 years
•2.The subject is willing to provide signed written informed consent.
•3.The subject is the recipient of a deceased donor kidney transplant.
•4.The donor and/or donor kidney meet at least one of the following extended criteria for organ donation from either (a) or (b) as described below:
•Donor conditionDonor age categories
•50-59 years>or=60 years
•CVA+HTN+SCr>1.5eligibleeligible
•CVA+HTN eligibleeligible
•CVA+SCr>1.5eligibleeligible
•HTN+SCr>1.5eligibleeligible
•CVA noeligible
•HTN no eligible
•SCr>1.5 noeligible
•None noeligible
•b)Additional criteria
•i)anticipated CIT = or > 24hrs
•ii)donor with cardiac death
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Women who are pregnant or breastfeeding.
•2. Women with a positive pregnancy test on enrolment.
•3. Subjects with any active infection that would normally exclude
•transplantation.
•4. Subjects who have used any other investigational drug within 30 days prior to
•transplantation.
•5. Subjects with a haemoglobin level = or > 15g/dl
•6. Subjects with a diastolic blood pressure > 100 mm/Hg pre-transplantation.
•7. Subjects previously intolerant of NeoRecormon.

发起方

Central Manchester and Manchester Children's University Hospitals NHS Trust